Connect with us

Technology

Global Flow Cytometry Market to Reach USD 11.14 Billion by 2034 at 9% CAGR as Rising Adoption in Clinical Diagnostics, Growing Multiparameter Cell Analysis, and Advances in High-Parameter Flow Cytometry Accelerate Market Growth, Reports Maximize Market Research

Published

1 day ago

on

PUNE, India, Sept. 23, 2026 /PRNewswire/ — The Global Flow Cytometry Market was valued at USD 5.13 Billion in 2025 and is projected to expand at a 9% CAGR from 2026 to 2034, reaching USD 11.14 Billion by 2034, according to a new analysis by Maximize Market Research.

Global Flow Cytometry Market

The Global Flow Cytometry Market Report 2025 provides a detailed analysis of market trends, growth drivers, technological advancements, clinical applications, research activities, product innovations, regulatory developments, competitive developments, applications, and market forecasts through 2034. The market covers Instruments, Reagents and Consumables, Software, and Services across Cell-based Flow Cytometry and Bead-based Flow Cytometry, with applications spanning academic and research institutes, hospitals and clinical testing laboratories, and pharmaceutical and biotechnology companies.

The growing adoption of flow cytometry in clinical diagnostics, oncology, immunology, cell biology, drug discovery, and life science research is supporting the expansion of the global flow cytometry market. Increasing demand for multiparameter cellular analysis, immunophenotyping, biomarker identification, cell-cycle analysis, and immune-cell characterization is strengthening the use of flow cytometry across research and clinical environments. Rising investments in biotechnology, pharmaceutical R&D, precision medicine, and cell-based research are further contributing to demand for advanced flow cytometry systems, reagents, consumables, and analytical software.

Advancements in spectral flow cytometry, high-parameter analysis, automated workflows, cell sorting, nanoscale particle analysis, and AI-enabled data interpretation are further transforming the flow cytometry landscape. Increasing research into cancer, immunotherapy, stem cells, cell and gene therapies, and single-cell analysis is creating new opportunities for market participants. Product launches, technological innovation, strategic collaborations, acquisitions, and expansion of clinical and research applications are expected to strengthen the global flow cytometry market through 2034.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/29653/ 

Global Flow Cytometry Market gains momentum as rising adoption in clinical diagnostics and life science research, increasing demand for multiparameter cell analysis, advances in spectral and high-parameter flow cytometry, automation, and expanding cell and gene therapy applications accelerate technological innovation: Maximize Market Research unveils key insights.

Global Flow Cytometry Market Size & Forecast

Parameter

Value

Market Size (Base Year 2025)

USD 5.13 Billion

Forecast Market Size (2034)

USD 11.14 Billion

CAGR (2026-2034)

9 %

Base Year

2025

Forecast Period

2026-2034

Historical Period

2020-2025

Global Flow Cytometry Market Trends & Insights

North America leads the Global Flow Cytometry Market, supported by advanced healthcare infrastructure, strong biomedical research activity, established pharmaceutical and biotechnology industries, and extensive adoption of flow cytometry in clinical diagnostics and life science research.Asia-Pacific represents a high-growth region, driven by expanding pharmaceutical and biotechnology sectors, improving healthcare infrastructure, increasing biomedical research investments, and growing adoption of advanced cellular analysis technologies across China, Japan, India, and South Korea.Rising demand for multiparameter cellular analysis is increasing the adoption of flow cytometry across oncology, immunology, drug development, cell biology, and clinical diagnostics, particularly for immunophenotyping, biomarker identification, cell-cycle analysis, and immune-cell characterization.Spectral and high-parameter flow cytometry technologies are gaining importance, supported by the need for detailed analysis of complex and heterogeneous cell populations. Advances in automation, cell sorting, nanoscale particle analysis, and integrated data-analysis software are further expanding technology adoption.Clinical research and cell-based therapy development are accelerating market innovation, with increasing applications in cancer research, immunotherapy, stem-cell studies, and cell and gene therapy. Product launches, technological advancements, R&D investments, and development of automated analytical workflows are creating new opportunities for flow cytometry market participants.

Growing Adoption of Multiparameter Cellular Analysis Drives Market Growth

The increasing use of flow cytometry in clinical diagnostics, oncology, immunology, cancer research, drug discovery, cell biology, and life science research is driving market growth. Rising demand for immunophenotyping, biomarker identification, cell-cycle analysis, immune-cell characterization, and high-resolution cellular analysis is encouraging laboratories to adopt advanced flow cytometers. The expanding use of flow cytometry in pharmaceutical R&D, biotechnology research, immunotherapy, stem-cell studies, and cell-based research is further supporting demand for instruments, reagents, consumables, software, and services.

High Capital and Operating Costs Restrain Market Growth

The substantial investment required for advanced flow cytometry instruments, lasers, detectors, reagents, specialized software, maintenance, laboratory infrastructure, and technical support can restrict adoption, particularly among smaller hospitals, academic laboratories, and research facilities with limited budgets. The increasing complexity of high-parameter and spectral flow cytometry systems, together with recurring consumable and maintenance requirements, can further increase the overall cost of ownership and limit adoption in cost-sensitive markets.

Expansion of Spectral Flow Cytometry and Cell-Based Therapies Creates Opportunities

Advancements in spectral flow cytometry, high-parameter analysis, automated workflows, cell sorting, nanoscale particle analysis, and advanced data-analysis software are creating significant opportunities in the flow cytometry market. Growing applications in single-cell analysis, immunotherapy, cancer research, stem-cell studies, and cell and gene therapy are increasing demand for technologies capable of characterizing complex cell populations at greater resolution. The development of AI-enabled analysis, workflow automation, integrated software solutions, and application-specific platforms is further expanding opportunities for technology providers.

Shortage of Skilled Professionals and Complex Data Interpretation Create Challenges

The increasing complexity of multiparameter and high-dimensional flow cytometry datasets creates challenges related to panel design, compensation, quality control, instrument operation, data management, and interpretation. Laboratories require skilled professionals with expertise in flow cytometry instrumentation, fluorescence analysis, cell sorting, assay development, and computational data analysis. The shortage of trained personnel, together with the complexity of analyzing multidimensional cellular datasets and maintaining standardized workflows, can create operational challenges for clinical and research laboratories.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/29653/ 

Global Flow Cytometry Market Segmentation

The Global Flow Cytometry Market is segmented by Component, Technology, End Use, and Region. Increasing adoption of multiparameter cellular analysis, growing applications in clinical diagnostics and life science research, technological advancements in spectral and high-parameter flow cytometry, rising pharmaceutical and biotechnology R&D investments, and expanding applications in cell-based therapies are supporting market development across these segments.

Segmentation

Sub-Segments

By Component

Instruments; Reagents and Consumables; Software; Services

By Technology

Cell-based Flow Cytometry; Bead-based Flow Cytometry

By End Use

Academic & Research Institutes; Hospitals & Clinical Testing Laboratories;
Pharmaceutical & Biotechnology Companies

By Region

North America; Europe; Asia Pacific; Middle East & Africa; South America

North America Leads the Flow Cytometry Market While Asia Pacific Emerges as a High-Growth Region

North America held the largest share of the Global Flow Cytometry Market in 2025, supported by advanced healthcare infrastructure, strong biomedical research activity, established pharmaceutical and biotechnology industries, and widespread adoption of advanced cellular analysis technologies. The United States represents a major market due to substantial healthcare and life science investments, extensive clinical laboratory networks, strong oncology and immunology research, and increasing use of flow cytometry in clinical diagnostics, drug discovery, immunotherapy, and cell-based research. Canada and Mexico also contribute through improving laboratory infrastructure, expanding research capabilities, and growing adoption of advanced flow cytometry systems.

Europe represents an important market, supported by established healthcare systems, strong clinical and academic research networks, pharmaceutical and biotechnology activity, and increasing use of flow cytometry in diagnostic and research applications. The United Kingdom, France, Germany, Italy, Spain, Sweden, Austria, and other European markets are witnessing continued adoption of multiparameter flow cytometry, spectral flow cytometry, cell sorting, immunophenotyping, and advanced data-analysis technologies. Growing investments in precision medicine, immunology, cancer research, and cell-based therapies are further supporting regional market development.

Asia Pacific is expected to witness strong growth as pharmaceutical and biotechnology industries expand alongside improvements in healthcare infrastructure and biomedical research capabilities. China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, and other regional markets are contributing to market development. Rising investments in cancer research, drug development, immunology, cell biology, cell and gene therapies, and life science research, together with increasing adoption of high-parameter and automated flow cytometry systems, are creating opportunities across the region.

Middle East & Africa is gradually developing as healthcare modernization, laboratory infrastructure development, and investment in advanced diagnostic and research capabilities increase. South Africa, GCC countries, Egypt, Nigeria, and other regional markets are contributing to market development through expanding clinical laboratories, biomedical research activities, and increasing access to advanced analytical technologies. Growing demand for clinical diagnostics, immunological testing, and specialized laboratory analysis is supporting the gradual adoption of flow cytometry.

South America is supported by improving healthcare infrastructure, expanding research activities, and increasing adoption of advanced diagnostic and laboratory technologies. Brazil represents an important regional market, while Argentina and other South American countries are contributing as pharmaceutical and biotechnology capabilities develop and demand increases for sophisticated cell analysis, immunophenotyping, oncology research, and clinical laboratory testing.

Leading Companies Strengthen the Flow Cytometry Technology Landscape

Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Danaher Corporation, Agilent Technologies, Luminex Corporation, Miltenyi Biotec GmbH, Bio-Rad Laboratories Inc., Merck KGaA, Sysmex Corporation, Sony Biotechnology Inc., Cytek Biosciences Inc., Bio-Techne Corporation, BioLegend Inc., and Sartorius AG are among the prominent companies associated with the global flow cytometry landscape. Their activities across flow cytometers, cell sorters, reagents and consumables, spectral flow cytometry, software, automation, and cell-analysis solutions are supporting technological development and commercialization. Companies are also focusing on product launches, R&D, strategic collaborations, acquisitions, workflow automation, and expansion of applications across clinical diagnostics, pharmaceutical research, biotechnology, and cell and gene therapy.

Global Flow Cytometry Market Competitive Landscape

The Global Flow Cytometry Market is increasingly technology-driven and application-oriented, with companies focusing on multiparameter flow cytometry, spectral flow cytometry, cell sorting, high-parameter analysis, automated workflows, nanoscale particle analysis, reagents and consumables, software, and integrated cell-analysis solutions. Key players include Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Danaher Corporation, Agilent Technologies, Miltenyi Biotec GmbH, Bio-Rad Laboratories Inc., Merck KGaA, Sysmex Corporation, Sony Biotechnology Inc., Cytek Biosciences Inc., Bio-Techne Corporation, BioLegend Inc., and Sartorius AG. Competition is shaped by instrument sensitivity, fluorescence detection capabilities, multiparameter analysis, automation, data-analysis software, workflow efficiency, application-specific solutions, product innovation, R&D investment, strategic collaborations, acquisitions, and expansion into clinical diagnostics, oncology, immunology, pharmaceutical research, and cell and gene therapy applications.

Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/checkout/29653/ 

Flow Cytometry Market, Key Players

Thermo Fisher Scientific, Inc.Becton, Dickinson and CompanyDanaher CorporationAgilent TechnologiesLuminex CorporationMiltenyi Biotec GmbHBio-Rad Laboratories, Inc.Merck KGaASysmex CorporationSony Biotechnology Inc.Stratedigm, Inc.Cytek Biosciences, Inc.Bio-Techne CorporationBioLegend, Inc.Sartorius AGApogee Flow SystemsThermoGenesis Holdings, Inc.Nexcelom Bioscience LLCUnion Biometrica, Inc.De Novo Software

Frequently Asked Questions:

What segments are covered in the Global Market report?
Ans. The segments covered in the Market report are based on Product & Service, By Technology Type, By End-use, and End-Use Industry.

Which region held the largest Market share in 2025?
Ans. The North America region held the largest Market share in 2025.

What is the expected Market size by 2032?
Ans. The Flow Cytometry Market size is expected to reach USD 11.14 Bn by 2034.

What was the key driver of the Global Flow Cytometry Market?
Ans. The factors driving the market growth include the rising R&D investments in the biotechnology sector and technological advancements in the field of flow cytometry for introducing new and improved analytical tools, such as microfluidic flow cytometry, for point-of-care testing.

What is the expected CAGR of the Global Market during the forecast period?
Ans. The expected CAGR of the Market is 9% during the forecast period.

Analyst Perspective

Analysts highlight that the Global Flow Cytometry Market is being driven by growing adoption of multiparameter cellular analysis across clinical diagnostics, oncology, immunology, cancer research, drug discovery, and life science research. Advances in spectral flow cytometry, high-parameter analysis, cell sorting, automation, and data-analysis software are expanding market applications. At the same time, high instrument and operating costs, complex workflows, and the shortage of skilled professionals remain key challenges. Growing research in single-cell analysis, immunotherapy, stem-cell studies, and cell and gene therapy, along with increasing pharmaceutical and biotechnology R&D, is creating new opportunities and expected to shape the market through 2034.

Related Reports:

Flow Cytometry Products Market by Technology, Modality, Component Type, End-Use, and Product – Global Forecast to 2034

Cell Sorting Market by Product, Technology, Cell Type, Cell Size, Application, End-User, and Region – Global Forecast to 2034

Cell Analysis Market by Product & Service, Technique, Process, End-User, and Region – Global Forecast to 2034

Cell Analysis Instruments Market by Panel Type, Application, End-User, and Region – Global Forecast to 2034

Single Cell Analysis Market by Product, Application, Technique, End-User, and Region – Global Forecast to 2034

About Maximize Market Research – Global Flow Cytometry Market

Maximize Market Research is a leading global market research and business consulting firm delivering data-driven insights across the Healthcare, Pharmaceuticals, Life Sciences, Biotechnology, and Medical Technology sectors, including the Global Flow Cytometry Market. Its research helps businesses understand evolving market trends, assess market dynamics, identify emerging opportunities, and evaluate developments across flow cytometry instruments, reagents and consumables, software, cell analysis technologies, spectral flow cytometry, and automated laboratory workflows.

Expertise in Flow Cytometry & Life Science Research

With expertise in healthcare, biotechnology, pharmaceuticals, and life sciences market research, Maximize Market Research provides insights into flow cytometry systems, cell-based and bead-based flow cytometry, multiparameter cellular analysis, immunophenotyping, cell sorting, spectral flow cytometry, high-parameter analysis, and advanced data-analysis solutions. Its research evaluates market trends, technological developments, clinical applications, R&D activities, product launches, competitive developments, and emerging applications across oncology, immunology, drug discovery, cell-based research, and cell and gene therapy, helping industry stakeholders identify growth opportunities across the global flow cytometry ecosystem.

Contact:
Lumawant Godage
MAXIMIZE MARKET RESEARCH PVT. LTD.
+91 96073 65656
Email: sales@maximizemarketresearch.com
Content Source: https://www.maximizemarketresearch.com/market-report/flow-cytometry-market/29653/
Visit Our Web Site: https://www.maximizemarketresearch.com/
LinkedIn.com: https://www.linkedin.com/company/maxmize-market-research-pvt-ltd/
Instagram: https://www.instagram.com/maximizemarketresearch/
Facebook: https://www.facebook.com/maximizemarketresearch/
X (Twitter): https://x.com/MMRAnalytics

 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/global-flow-cytometry-market-to-reach-usd-11-14-billion-by-2034-at-9-cagr-as-rising-adoption-in-clinical-diagnostics-growing-multiparameter-cell-analysis-and-advances-in-high-parameter-flow-cytometry-accelerate-market-growth-r-302887663.html

Related Topics:
Continue Reading

Technology

MetaOptics Ltd establishes American Depositary Receipt (“ADR”) Programme on OTCQX in the U.S., with J.P. Morgan as the Depositary Bank

Published

9 minutes ago

on

September 25, 2026

By

SINGAPORE, Sept. 25, 2026 /PRNewswire/ — MetaOptics Ltd (Catalist: 9MT) (“MetaOptics” or the “Company”, and together with its subsidiaries, the “Group”), a leading-edge semiconductor optics company, today announced the establishment of its sponsored Level 1 ADR programme in the U.S. (the “ADR Programme”), under which American Depositary Shares (“ADSs”) will trade on OTCQX.

The Company has appointed J.P. Morgan as the depositary bank for the ADR Programme. The ADR Programme does not involve any capital raising or the issuance of new shares by the Company. The Company’s ordinary shares will continue to trade on the Catalist board of the SGX Stock Exchange and the ADR Programme is not expected to have any material impact to existing shareholders of the Company.

Trading on OTCQX, the highest-level market of Over The Counter (“OTC”) Markets

OTCQX is the highest-level market operated by OTC Markets Group, which operates regulated markets for more than 12,000 U.S. and international securities. OTCQX is designed for established, investor-focused U.S. and international companies and requires companies to meet prescribed financial standards, follow best-practice corporate governance and demonstrate compliance with applicable securities laws.

Joining a growing group of Singapore-listed companies accessible to U.S. investors

The Company’s ADR Programme on OTCQX places it within a broader ecosystem of Singapore-listed companies whose shares are also accessible to U.S. investors. These include prominent names such as Singapore Exchange Ltd. (SGX Group), which also trades on OTCQX.

Expanding the Company’s global shareholder base

Following the Company’s successful listing on the Catalist of the SGX-ST in September 2025, its participation in CES 2025 and CES 2026, as well as recent product and technology roadshows in the U.S., the Group’s engagement and collaboration with U.S. industry partners, customers and institutional investors, has validated its growth and expansion plans in the U.S. including the establishment of the Group’s maiden front-end semiconductor fabrication line with 12-inch DUV immersion photolithography equipment in the U.S., for the mass production of metalenses and modules. With the Group’s continued and ongoing expansion in the U.S., the ADR Programme is intended to broaden the Company’s international investor reach and provide U.S.-based investors with a more convenient channel to access and trade the Company’s securities, and to provide a platform for U.S. investors to directly participate in the Company’s growth story. The Company believes that greater access to U.S. investors will be particularly relevant as it progresses its next phase of commercialisation and development.

In addition, the ADR Programme will provide Singapore-based investors around-the-clock access to trade in the Company’s shares, via OTCQX and its local listing on the SGX Stock Exchange. The ADS conversion can be effected through J.P. Morgan as the Company’s depositary bank, and trading of the ADSs through U.S. brokers and trading platforms. Singapore-based investors who wish to trade in the ADSs through Singapore-based brokers and trading platforms, are able to do so via such brokers and trading platforms, and can reach out to their respective trading representatives for further details.

Investors who wish to find out more about the conversion and/or ADSs issuance on OTCQX may refer to https://adr.com/ for the related forms and instructions. J.P. Morgan’s Settlement and Operations team will also be available to assist investors and/or their brokers, and can be contacted at jpm.adr.settlements@jpmorgan.com.

Supporting the Group’s commercialisation and collaboration in the U.S.

The ADR Programme complements the Company’s deployment of its key direct laser writers (“DLW”) at the nano@stanford facility and the University of Arizona’s Centre of Semiconductor Manufacturing, to further expand the Group’s engagement within the U.S. technology and research ecosystems, and support the Group’s U.S. expansion strategy, prospective U.S. customer engagement, and commercialisation roadmap, including the establishment of the Group’s maiden front-end semiconductor fabrication line with 12-inch DUV immersion photolithography equipment in the U.S., for the mass production of metalenses and modules.

Mr Thng Chong Kim, Executive Chairman said “The ADR Programme on OTCQX provides us an additional platform to introduce and increase awareness of our technology and solutions, and provides U.S. investors with a dedicated and accessible trading channel for our shares, which will help us broaden our shareholder base, enhance the potential for liquidity and international visibility, and bring our growth story to a wider investment community. This is particularly relevant, as we progress on our next phase of commercialisation and expansion in the U.S..”

About MetaOptics Ltd

MetaOptics Ltd (Catalist: 9MT) is a leading-edge semiconductor optics company pioneering glass-based metalens solutions enhanced by AI-driven image processing. Using advanced optical design and a scalable 12-inch DUV lithography process, it powers next-generation applications in CPO, mobile, AR VR, automotive and other emerging markets. Headquartered in Singapore, MetaOptics aims to deliver high-performance optics with the reliability and scalability demanded by today’s most innovative technology brands. Find out more at www.metaoptics.sg.

Forward-Looking Statements

This press release may contain forward-looking statements that involve known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the Company’s growth strategies, its future business development, results of operations and financial condition, its research and development efforts, its ability to attract and retain customers, and its ability to establish and maintain relationships with suppliers and business partners; and assumptions underlying or related to any of the foregoing. All information provided in this press release is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Singapore (Headquarters)

MetaOptics Technologies Pte Ltd, 81 Ayer Rajah Crescent, #01-45, Singapore 139967

United States

MetaOptics Inc. (USA), 1 Ferry Building, Suite 201, San Francisco, CA 94111

View original content:https://www.prnewswire.com/apac/news-releases/metaoptics-ltd-establishes-american-depositary-receipt-adr-programme-on-otcqx-in-the-us-with-jp-morgan-as-the-depositary-bank-302889875.html

SOURCE METAOPTICS LTD

Continue Reading

Technology

H2O.ai’s Singapore Lab Aims to Turn the Republic From AI User to AI Maker

Published

9 minutes ago

on

September 25, 2026

By

H2O.ai founder Sri Ambati on why Singapore’s constraints and demanding market make it a testbed for sovereign AI.

SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Sri Ambati, founder and chief executive of H2O.ai, spoke to Kestone Global about why the company has set up a forward deployed AI lab in Singapore, and what he thinks a small, land-scarce country can pull off that bigger ones can’t.

Kestone Global: Singapore is small, short on land and has an ageing population. Why build here rather than somewhere with more room to grow?

Ambati: Because those limits do some of the work for us. When you don’t have spare land or spare people, you end up leaning on AI and robotics just to keep productivity moving, so the pressure to get it right is higher here than in most places we operate. And the customers are demanding. Government agencies, private companies, they’re already AI-literate, so our products get pushed harder in Singapore than they would somewhere more forgiving. I’d rather build against that kind of resistance than in a market that lets us coast.

Kestone Global: You talk a lot about “Sovereign AI.”What does that actually mean for a country like Singapore?

Ambati: I’d compare it to a power grid, or water supply. You either own and control your core AI systems or you don’t, and using something isn’t the same as owning it. A country becomes AI-sovereign when it can diagnose a model, debug it, improve it, build on it, not just license someone else’s and stop there. For Singapore that means building up local data, local infrastructure and local talent, instead of importing all three off the shelf.

Kestone Global: How do you actually build that local talent base, in practice?

Ambati: We put local engineers on live projects next to our most senior people, some of whom are Kaggle Grandmasters. Not a course, not a workshop, an actual project with actual stakes. Sitting next to someone who’s already solved the hard version of your problem teaches you faster than any curriculum does, and honestly Singapore starts ahead with her strong university ecosystem and community-centric culture, so we’re not starting from zero.

Kestone Global: That’s the talent side. What about the delivery model? How does H2O.aiactually get these projects into production?

Ambati: Forward deployment. Senior engineers sit physically close to the customer instead of running things remotely from some head office. It’s a product decision, not just a staffing one. Spend enough time inside a bank or a hospital and you find the gaps a demo would never show you, and it’s closing those gaps, not polishing the pitch deck, that actually matters. What we’re after is getting past the demo and into something that produces a return you can measure. We call that the last mile.

Kestone Global: What kinds of local problems is the lab aiming to take on?

Ambati: A few things are on the list. On financial crime, the idea is to build models that catch scams earlier, and to go a step further with AI bots that pretend to be potential victims, tying up a scammer’s time and pulling intelligence out of the conversation. We also want to look at robots that can safely help elderly residents, and at predicting lightning strikes near high-rise buildings, both shaped by how dense Singapore is and by its climate, so any model would need guardrails tuned to local conditions rather than a generic template pulled from somewhere else. In healthcare, women’s health is underfunded, and that’s an area where I’d like to move quickly with local hospitals. More broadly, I think the nearest payoff from AI shows up in science and medicine, where it can cut years off getting to a discovery.

Kestone Global: Where does this mission come from, personally?

Ambati: My mother was diagnosed with cancer, and that’s really where it started. I wanted AI pointed at the disease directly, and that turned into something bigger for me: making AI cheap enough, fast enough, easy enough that it becomes ordinary. Like water. If it costs less to run, more people get to experiment with it instead of a handful of well-funded labs deciding what gets built. That’s not a slogan we put on a slide, either. It’s the reason we’ve managed to pull in people to work on things like counting endangered species, alongside the paid healthcare work.

Kestone Global: Zooming out, what does the world look like by the end of this decade?

Ambati: I think AI adds more than US$100 trillion to global GDP by 2030 and beyond, and I want human health and longevity to be somewhere in that story with H2O.ai’s name on it. The shape of the technology itself is going to change too. Today’s large models are dinosaurs, honestly, and better data, including synthetic data, should push things toward small language models that can run on a device rather than a data center. After that, physical AI, robots, is the next big shift, and I’d bet it moves faster and matters more than most people expect. Space exploration too.

Kestone Global: So what’s the immediate test, here in Singapore?

Ambati: Whether a small country with real constraints can become a maker of AI instead of just a customer for it. If that works, other countries chasing the same thing get a blueprint they can actually use, one built on co-creating with local partners, on returns you can measure, and on homegrown people, not just a licensed product shipped in from somewhere else.

About H2O.ai

H2O.ai is an artificial intelligence company founded by Sri Ambati, built around a mission to democratize AI by making it faster, cheaper and easier to use. Its platform integrates predictive, generative and agentic AI, and the company works with governments and enterprises worldwide, including through forward deployed labs such as its new Singapore initiative, to co-create localized AI solutions across sectors including finance, healthcare and public safety. H2O.ai’s long-term vision centers on “AI for good,” applying AI to major scientific, economic and societal challenges, with particular focus on advancing human health and longevity.

Media Contact

Name: Norris Liew
Email: norris.l@kestoneglobal.com
Phone: 96278813

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/h2oais-singapore-lab-aims-to-turn-the-republic-from-ai-user-to-ai-maker-302884399.html

SOURCE Kestone CL Asia Hub Pte Ltd

Continue Reading

Technology

Loyalty Juggernaut Advances Responsible AI with ISO/IEC 42001 Certification

Published

9 minutes ago

on

September 25, 2026

By

British Standards Institution certifies the AI management system governing GRAVTY®’s pioneering Agentic Systems portfolio.

PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ — Global loyalty technology leader Loyalty Juggernaut today announced that it has achieved ISO/IEC 42001:2023 certification for its Artificial Intelligence Management System, which governs the development, deployment, oversight and continual improvement of AI capabilities within its GRAVTY® platform. The certified scope encompasses AI systems using supervised and unsupervised learning and large language models to support hyper-personalized engagement, fraud management, loyalty intelligence, autonomous decision-making and loyalty operations.

An internationally recognized management system standard, ISO/IEC 42001 provides a structured framework for managing AI-related risks while promoting responsible governance, transparency, accountability and security throughout the AI lifecycle.

Within this certified management system, GRAVTY® brings together six Agentic Systems designed to help loyalty programs continuously sense, analyze, decide, act and learn:

Program Intelligence System: Transforms program data into actionable insights, forecasts and strategic recommendations.Personalization System: Orchestrates individualized offers and experiences at scale.Growth and Retention System: Identifies opportunities to acquire, engage, retain and grow customers.Commerce and Experience System: Connects loyalty, commerce and customer experiences across the loyalty ecosystem.Trust and Risk System: Detects anomalies, mitigates fraud and strengthens program integrity.Productivity and Workflow System: Automates complex operational workflows and augments human decision-making.

“Agentic AI marks a fundamental shift from systems that provide intelligence to systems that interpret conditions, recommend strategies, take coordinated action and learn from outcomes,” said Kalpak Shah, Co-founder and Chief Technology Officer at Loyalty Juggernaut. “ISO/IEC 42001 certification validates the rigorous management system behind our AI innovation, giving clients greater confidence that GRAVTY®’s AI capabilities are developed and deployed with strong governance, transparency, security, accountability and human oversight.”

“AI will play an increasingly important role in shaping the future of loyalty, but innovation must go hand in hand with trust and responsible governance,” said Dr. Nejib Ben Khedher, Head of Emirates Skywards. “Loyalty Juggernaut’s ISO/IEC 42001 certification provides an important level of assurance as we explore next-generation capabilities within GRAVTY®. Ultimately, our focus is on using AI to create greater value for our members while ensuring that transparency, accountability and trust remain at the heart of how we innovate.”

The certification builds on Loyalty Juggernaut’s broader commitment to enterprise-grade security, privacy, reliability and responsible innovation.

About Loyalty Juggernaut

Loyalty Juggernaut is the leading provider of enterprise loyalty technology. Its cloud-native, patented GRAVTY® platform enables brands to design, operate and continuously optimize sophisticated loyalty ecosystems at scale. Loyalty Juggernaut serves clients across airlines, hospitality, retail, financial services, telecommunications and diversified business groups worldwide.

About Emirates

Founded in 1985, Emirates is a global connector of people, places and economies. Based in Dubai, the airline’s global network serves more than 146 destinations in 81 countries across six continents. Its luxurious amenities, regionally inspired gourmet cuisine, award-winning in-flight entertainment system and the unmatched hospitality of its iconic multilingual cabin crew have made Emirates one of the world’s most recognized airline brands.

Media Contact: media@lji.io

 

SOURCE Loyalty Juggernaut, Inc.

Continue Reading

Trending